nanobodies market size is estimated to be usd 91.3 million in 2020 and is projected to reach usd 628.5 million by 2028.
July 17, 2020 06:30 ET
|
Quince Market Insights
Pune, India, July 17, 2020 (GLOBE NEWSWIRE) -- The Global Nanobodies Market Size is estimated to be USD 91.3 million in 2020 and is projected to reach USD 628.5 million by 2028. Nanobodies also...
New Study Ranks Performance of Currently Available COVID-19 Antibody Tests
July 15, 2020 13:00 ET
|
NSF International
Ann Arbor, MI, July 15, 2020 (GLOBE NEWSWIRE) -- A new peer-reviewed study by researchers at NSF International and Novateur Ventures finds significant variability in the accuracy of currently...
Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in China
July 12, 2020 20:00 ET
|
Junshi Biosciences
SHANGHAI, China, July 12, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics
June 08, 2020 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9...
Sorrento Receives FDA IND Clearance to Initiate a Phase I Clinical Trial of its CD38 Antibody-Drug Conjugate (ADC) STI-6129 for Patients with Amyloidosis
May 26, 2020 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for its...
Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China
January 06, 2020 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (Nasdaq: SRNE) announced today that its partner Mabpharm (HK:2181) filed recently a New Drug Application for the Infliximab...
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
December 19, 2019 11:05 ET
|
CureVac AG
Company Announcement Genmab and CureVac enter broad strategic partnership Companies to conduct joint research on first program; option for Genmab to initiate three additional programs during 5-year...
Teneobio’s Lead Candidate, TNB-383B, Receives Orphan Drug Designation from the FDA for the Treatment of Multiple Myeloma
November 06, 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Teneobio Licenses Oncology Multispecific Product to Janssen
September 30, 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Batavia Biosciences to deploy Horizon Discovery’s CHO cell technology to develop anti-Zika biotherapeutic with Vanderbilt University Medical Center and IDBiologics
September 03, 2019 08:00 ET
|
Batavia Biosciences B.V.
Leiden, 3 September 2019 – Today, Batavia Biosciences announced that the company has signed a license agreement to utilize Horizon Discovery’s GS knockout CHO K1 cell line expression system for the...